Načítá se...
Renal allograft rejection after treatment with nivolumab in patients with metastatic renal cell carcinoma
In recent years, immune checkpoint inhibitors (ICIs), such as nivolumab, pembrolizumab and ipilimumab, have been introduced into routine clinical practice for treating patients with several types of advanced cancer, including renal cell carcinoma (RCC). However, activation of the immune system again...
Uloženo v:
| Vydáno v: | Int Cancer Conf J |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer Singapore
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7947052/ https://ncbi.nlm.nih.gov/pubmed/33786286 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13691-020-00458-8 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|